Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...
New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...
Clinical Trials Arena on MSN1d
Amgen’s gMG therapy cuts disease symptoms at one-year markResults from the company’s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom ...
With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...
US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).
Amgen has shared additional Phase 3 data for its rare disease drug Uplizna in myasthenia gravis, bolstering the company’s ...
Oppenheimer reiterates a Perform rating on Cartesian Therapeutics (RNAC) without a price target following the company’s Q4 report. The ...
Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback